Canagliflozin for Japanese patients with chronic heart failure and type II diabetes

BACKGROUND: Reports that sodium glucose cotransporter 2 inhibitors decrease cardiovascular death and events in patients with diabetes have attracted attention in the cardiology field. We conducted a study of canagliflozin in patients with chronic heart failure and type II diabetes. METHODS: Thirty-f...

Descripción completa

Detalles Bibliográficos
Autores principales: Sezai, Akira, Sekino, Hisakuni, Unosawa, Satoshi, Taoka, Makoto, Osaka, Shunji, Tanaka, Masashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6551875/
https://www.ncbi.nlm.nih.gov/pubmed/31167663
http://dx.doi.org/10.1186/s12933-019-0877-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6551875/
https://www.ncbi.nlm.nih.gov/pubmed/31167663
http://dx.doi.org/10.1186/s12933-019-0877-2

Ejemplares similares